Full metadata record
DC pole | Hodnota | Jazyk |
---|---|---|
dc.contributor.author | Ostašov, Pavel | |
dc.contributor.author | null, null | |
dc.contributor.author | Robertson, Henry | |
dc.contributor.author | Piazza, Paolo | |
dc.contributor.author | Datta, Avik | |
dc.contributor.author | Apperley, Jane | |
dc.contributor.author | Houdová, Lucie | |
dc.contributor.author | Lysák, Daniel | |
dc.contributor.author | Holubová, Monika | |
dc.contributor.author | Tesařová, Kateřina | |
dc.contributor.author | Caputo, Valentina S. | |
dc.contributor.author | Barozzi, Iros | |
dc.date.accessioned | 2021-03-15T11:00:27Z | - |
dc.date.available | 2021-03-15T11:00:27Z | - |
dc.date.issued | 2020 | |
dc.identifier.citation | OSTAŠOV, P. ROBERTSON, H. PIAZZA, P. DATTA, A. APPERLEY, J. HOUDOVÁ, L. LYSÁK, D. HOLUBOVÁ, M. TESAŘOVÁ, K. CAPUTO, VS. BAROZZI, I.Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. Frontiers in Oncology, 2020, roč. 10, č. OCT 2020, s. 1-9 (article 584607). ISSN 2234-943X. | cs |
dc.identifier.issn | 2234-943X | |
dc.identifier.uri | 2-s2.0-85096052038 | |
dc.identifier.uri | http://hdl.handle.net/11025/42923 | |
dc.format | 9 s. | cs |
dc.format.mimetype | application/pdf | |
dc.language.iso | en | en |
dc.publisher | Frontiers Media | en |
dc.relation.ispartofseries | Frontiers in Oncology | en |
dc.rights | © Frontiers Media | en |
dc.title | Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report | en |
dc.type | článek | cs |
dc.type | article | en |
dc.rights.access | openAccess | en |
dc.type.version | publishedVersion | en |
dc.description.abstract-translated | Genetic and transcriptional heterogeneity of Chronic lymphocytic leukaemia (CLL) limits prevention of disease progression. Longitudinal single-cell transcriptomics represents the state-of-the-art method to profile the disease heterogeneity at diagnosis and to inform about disease evolution. Here, we apply single-cell RNA-seq to a CLL case, sampled at diagnosis and relapse, that was treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) and underwent a dramatic decrease in CD19 expression during disease progression. Computational analyses revealed a major switch in clones’ dominance during treatment. The clone that expanded at relapse showed 17p and 3p chromosomal deletions, and up-regulation of pathways related to motility, cytokine signaling and antigen presentation. Single-cell RNA-seq uniquely revealed that this clone was already present at low frequency at diagnosis, and it displays feature of plasma cell differentiation, consistent with a more aggressive phenotype. This study shows the benefit of single-cell profiling of CLL heterogeneity at diagnosis, to identify clones that might otherwise not be recognized and to determine the best treatment options. | en |
dc.subject.translated | chronic lymphoid leukemia (CLL) | en |
dc.subject.translated | single-cell RNA-seq (scRNA-seq) | en |
dc.subject.translated | therapy resistance | en |
dc.subject.translated | disease progression | en |
dc.subject.translated | advanced disease | en |
dc.subject.translated | case report | en |
dc.identifier.doi | 10.3389/fonc.2020.584607 | |
dc.type.status | Peer-reviewed | en |
dc.identifier.document-number | 589084000001 | |
dc.identifier.obd | 43930592 | |
Vyskytuje se v kolekcích: | Články / Articles (NTIS) OBD |
Soubory připojené k záznamu:
Soubor | Velikost | Formát | |
---|---|---|---|
Frontier2020_Ostasov_Evolution_of_Advanced.pdf | 2,19 MB | Adobe PDF | Zobrazit/otevřít |
Použijte tento identifikátor k citaci nebo jako odkaz na tento záznam:
http://hdl.handle.net/11025/42923
Všechny záznamy v DSpace jsou chráněny autorskými právy, všechna práva vyhrazena.